发布求助
文献互助 智能选刊 最新文献

International Journal of Hematologic Oncology最新文献

筛选
英文 中文
Brentuximab: a major advance in treatment of CD30-positive malignancies Brentuximab:治疗cd30阳性恶性肿瘤的重大进展
International Journal of Hematologic Oncology Pub Date : 2015-12-01 DOI: 10.2217/IJH.15.27
P. Amarapurkar, J. Rosenblatt, D. Pereira
{"title":"Brentuximab: a major advance in treatment of CD30-positive malignancies","authors":"P. Amarapurkar, J. Rosenblatt, D. Pereira","doi":"10.2217/IJH.15.27","DOIUrl":"https://doi.org/10.2217/IJH.15.27","url":null,"abstract":"Antibody-directed therapies allow greater selectivity in targeting of tumor associated antigens and spare normal cells. Brentuximab vedotin is an anti-CD30 antibody–drug conjugate. It has demonstrated impressive activity in the treatment of refractory and or relapsed Hodgkin's lymphoma, anaplastic large cell lymphoma and other CD30+ lymphoid malignancies. Several ongoing trials are testing the potential use of brentuximab vedotin for treatment of various CD30+ and CD30- malignancies in the setting of high-risk untreated disease. It is being tested in combination with chemotherapy, and testing in combination with immune therapy is also planned. CD30 plays a pivotal role in immune regulation and is also an attractive new target for intervention in the setting of select auto-immune diseases, as well as graft versus host disease.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"9 1","pages":"219-232"},"PeriodicalIF":0.0,"publicationDate":"2015-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.27","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
An interview with David Henry: supportive oncology, anemia and cancer 采访大卫·亨利:支持性肿瘤学，贫血和癌症
International Journal of Hematologic Oncology Pub Date : 2015-11-23 DOI: 10.2217/IJH.15.17
D. Henry
{"title":"An interview with David Henry: supportive oncology, anemia and cancer","authors":"D. Henry","doi":"10.2217/IJH.15.17","DOIUrl":"https://doi.org/10.2217/IJH.15.17","url":null,"abstract":"David H Henry, MD, is a practicing hematologist/medical oncologist and Clinical Professor of Medicine at the Pennsylvania Hospital in Philadelphia (PA, USA), where he holds the title of Vice Chairman of the Department of Medicine. He is Editor in Chief of the Journal of Community and Supportive Oncology. For the past 25 years, he has had a special interest in supportive oncology and participated in clinical trials using growth factors to treat cancer-related anemia with or without intravenous iron, neutropenia, thrombocytopenia and bone metabolism due to bone metastases. He is also the Director of the HIV Malignancy Program and Director of the Austrian Medical Student Program at Pennsylvania Hospital.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"129-131"},"PeriodicalIF":0.0,"publicationDate":"2015-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.17","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Current status of checkpoint inhibitors in lymphoma 检查点抑制剂在淋巴瘤中的现状
International Journal of Hematologic Oncology Pub Date : 2015-11-23 DOI: 10.2217/IJH.15.18
M. Jamil, Vipin Lohiya, A. Mehta
{"title":"Current status of checkpoint inhibitors in lymphoma","authors":"M. Jamil, Vipin Lohiya, A. Mehta","doi":"10.2217/IJH.15.18","DOIUrl":"https://doi.org/10.2217/IJH.15.18","url":null,"abstract":"Cancer immunotherapy is evolving very fast. With understanding of tumor and immune system interactions, two pathways have been identified through which tumor cells evade and escape immune system. Blocking these pathways by monoclonal antibodies has shown promising results in wide variety of tumors. The treatment of lymphomas have been evolving with various new molecules ranging from monoclonal antibodies, antibody–drug conjugates to small molecule inhibitors. Here, we review the activity of immune checkpoint inhibitors in various lymphomas. These agents have shown very promising activity in Hodgkin lymphoma and other B-cell lymphomas in early-phase clinical trials.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"167-174"},"PeriodicalIF":0.0,"publicationDate":"2015-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.18","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterization and targeting of neoplastic stem cells in Ph+ chronic myeloid leukemia Ph+慢性髓性白血病肿瘤干细胞的特征和靶向研究
International Journal of Hematologic Oncology Pub Date : 2015-11-23 DOI: 10.2217/IJH.15.16
M. Arock, F. Mahon, P. Valent
{"title":"Characterization and targeting of neoplastic stem cells in Ph+ chronic myeloid leukemia","authors":"M. Arock, F. Mahon, P. Valent","doi":"10.2217/IJH.15.16","DOIUrl":"https://doi.org/10.2217/IJH.15.16","url":null,"abstract":"Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of an oncogenic fusion gene, BCR–ABL1. This fusion gene produces a cytoplasmic protein with tyrosine kinase activity that acts as a main driver of oncogenesis and abnormal proliferation of myeloid cells in CML. Targeted therapy with BCR–ABL1 tyrosine kinase inhibitors (TKIs) such as imatinib is followed by long-term responses in most patients. However, despite continuous treatment, relapses occur, suggesting the presence of TKI-resistant neoplastic stem cells in these patients. Here, we discuss potential mechanisms and signaling molecules involved in the prosurvival and self-renewal capacity of CML neoplastic stem cells as well as antigens expressed by these cells. Several of these signaling molecules and cell surface antigens may serve as potential targets of therapy and their use may overcome TKI resistance in CML in the future.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"151-165"},"PeriodicalIF":0.0,"publicationDate":"2015-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.16","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221360","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Incidence of chromosomal anomalies detected by interphase FISH in chronic lymphoid leukemia 慢性淋巴细胞白血病间期FISH检测染色体异常的发生率
International Journal of Hematologic Oncology Pub Date : 2015-11-23 DOI: 10.2217/IJH.15.19
M. Braekeleer, M. L. Bris, A. Basinko, F. Morel, N. Douet-Guilbert
{"title":"Incidence of chromosomal anomalies detected by interphase FISH in chronic lymphoid leukemia","authors":"M. Braekeleer, M. L. Bris, A. Basinko, F. Morel, N. Douet-Guilbert","doi":"10.2217/IJH.15.19","DOIUrl":"https://doi.org/10.2217/IJH.15.19","url":null,"abstract":"Aims & methods: We used interphase FISH to determine the incidence of chromosomal changes in 638 B-cell chronic lymphocytic leukemia patients. Results: Chromosomal abnormalities were found in some 75% of the patients. Del(13)(q14) was present in 57.3 and 57% of patients at diagnosis and during follow-up, respectively. It was followed by trisomy 12 (19 and 19.8% at diagnosis and during follow-up, respectively), del(11)(q22) (9.1 and 14.3% at diagnosis and during follow-up, respectively) and del(17)(p13) (2.8 and 12.4% at diagnosis and during follow-up, respectively). Discussion & conclusion: Our results correlate with those obtained in 55 studies reported in the literature. Trisomy 12 and del(13)(q14) are present in high proportions at diagnosis and are not enriched during progression, to the contrary of del(11)(q22) and del(17)(p13) that are markers of evolution.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"133-141"},"PeriodicalIF":0.0,"publicationDate":"2015-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.19","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Recent advances in diagnosis and treatment of hairy cell leukemia 毛细胞白血病的诊断与治疗新进展
International Journal of Hematologic Oncology Pub Date : 2015-11-12 DOI: 10.2217/IJH.15.23
Asad Javed, Upasana Joneja, J. Gong, G. Uppal
{"title":"Recent advances in diagnosis and treatment of hairy cell leukemia","authors":"Asad Javed, Upasana Joneja, J. Gong, G. Uppal","doi":"10.2217/IJH.15.23","DOIUrl":"https://doi.org/10.2217/IJH.15.23","url":null,"abstract":"Hairy cell leukemia (HCL) is a rare, indolent B-cell lymphoproliferative disorder that accounts for 2% of all cases of leukemia. Most patients present with pancytopenia and splenomegaly with variable number of ‘hairy’ lymphocytes in blood. BRAF V600E mutation can be detected in virtually 100% of HCL cases and is absent in other B-cell lymphomas. The mutated gene and its responding abnormal protein can be used as specific markers in the diagnosis of HCL. New therapeutic modalities targeting on mutated BRAF and its downstream pathways have shown encouraging results in clinical trials. The objective of this review article is to discuss the recent developments in the diagnosis and management of hairy cell leukemia.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"33 1","pages":"191-200"},"PeriodicalIF":0.0,"publicationDate":"2015-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.23","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on recurrent genetic aberrations in acute myeloid leukemia 急性髓性白血病复发性基因畸变研究进展
International Journal of Hematologic Oncology Pub Date : 2015-11-10 DOI: 10.2217/IJH.15.22
K. Jamani, C. Owen
{"title":"Update on recurrent genetic aberrations in acute myeloid leukemia","authors":"K. Jamani, C. Owen","doi":"10.2217/IJH.15.22","DOIUrl":"https://doi.org/10.2217/IJH.15.22","url":null,"abstract":"Recurrent chromosomal aberrations have long been recognized to influence prognosis in acute myeloid leukemia (AML), however, 50% of AML patients have a normal karyotype. The new millennium ushered in discoveries of gene mutations at the molecular level that predict outcome in patients with normal karyotype. Some recurrent mutations are already used in routine practice for AML risk stratification. With the development of high-throughput sequencing technologies, there has been a storm of new data, uncovering a complex genetic landscape in AML. In this review, we describe the significant progress in characterizing recurrent genetic abnormalities in AML in the last 5 years, focusing on prognostic significance and therapeutic implications.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"179-190"},"PeriodicalIF":0.0,"publicationDate":"2015-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.22","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation 异体造血干细胞移植后供体淋巴细胞输注
International Journal of Hematologic Oncology Pub Date : 2015-11-10 DOI: 10.2217/IJH.15.20
T. Pereira, R. Danby, V. Rocha
{"title":"Donor lymphocyte infusion after allogeneic hematopoietic stem cell transplantation","authors":"T. Pereira, R. Danby, V. Rocha","doi":"10.2217/IJH.15.20","DOIUrl":"https://doi.org/10.2217/IJH.15.20","url":null,"abstract":"Donor lymphocyte infusion, a rescue therapy after hematopoietic stem cell transplantation, has been increasingly adopted, as modalities of stem cell transplantation have widened. First described as donor lymphocyte transfusion or cell therapy, it consists of infusion of donor lymphocytes, collected in steady state or after growth factor enhancement. As in literature the most used name is donor lymphocyte infusion, we'll adopt it here. Its most striking efficacy is observed in patients with chronic myelogenous leukemia, who relapsed after allogeneic stem cells transplantation. However, graft-versus-host disease, its main complication, may still hamper its feasibility.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"201-210"},"PeriodicalIF":0.0,"publicationDate":"2015-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.20","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221474","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ibrutinib in chronic lymphocytic leukemia 依鲁替尼治疗慢性淋巴细胞白血病
International Journal of Hematologic Oncology Pub Date : 2015-10-20 DOI: 10.2217/IJH.15.15
N. Reddy, Tarsheen K Sethi
{"title":"Ibrutinib in chronic lymphocytic leukemia","authors":"N. Reddy, Tarsheen K Sethi","doi":"10.2217/IJH.15.15","DOIUrl":"https://doi.org/10.2217/IJH.15.15","url":null,"abstract":"Chronic lymphocytic leukemia is a mature B-cell neoplasm in which the interactions between the malignant B cells and tumor microenvironment play a key role in cell survival and growth. B-cell receptor (BCR) is a key survival pathway in chronic lymphocytic leukemia. Following BCR signal trigger, several kinase pathways are activated that promote signal transduction. Ibrutinib is a first-in-class, potent, orally administered covalently binding inhibitor of Bruton's tyrosine kinase that is US FDA approved. Inhibition of Bruton's tyrosine kinase blocks downstream BCR signaling pathways (AKT, ERK) and thus prevents B-cell proliferation. Ibrutinib impairs microenvironment-induced survival of the malignant B cells. Ibrutinib is currently under investigation for both hematologic and solid tumor malignancies.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"143-150"},"PeriodicalIF":0.0,"publicationDate":"2015-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.15","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221695","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment of chronic myeloid leukemia, which drugs? How long? How much? 治疗慢性髓性白血病，有哪些药物?多久?多少钱?
International Journal of Hematologic Oncology Pub Date : 2015-10-12 DOI: 10.2217/IJH.15.14
M. Baccarani
{"title":"Treatment of chronic myeloid leukemia, which drugs? How long? How much?","authors":"M. Baccarani","doi":"10.2217/IJH.15.14","DOIUrl":"https://doi.org/10.2217/IJH.15.14","url":null,"abstract":"“...the already excellent results of treatment can be optimized, but optimization aiming at a sustainable extension of the treatment worldwide, at a more cost-effective use of the available drugs and at more attention to the quality of life, requires a long and a demanding learning curve.”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":"4 1","pages":"93-97"},"PeriodicalIF":0.0,"publicationDate":"2015-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/IJH.15.14","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68221451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信